[go: up one dir, main page]

AR131189A2 - Proceso para producir derivado de diazabiciclooctano y su intermediario - Google Patents

Proceso para producir derivado de diazabiciclooctano y su intermediario

Info

Publication number
AR131189A2
AR131189A2 ARP230103208A ARP230103208A AR131189A2 AR 131189 A2 AR131189 A2 AR 131189A2 AR P230103208 A ARP230103208 A AR P230103208A AR P230103208 A ARP230103208 A AR P230103208A AR 131189 A2 AR131189 A2 AR 131189A2
Authority
AR
Argentina
Prior art keywords
producing
iii
formula
compound
diazabiciclooctone
Prior art date
Application number
ARP230103208A
Other languages
English (en)
Inventor
Abe Takao
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR131189A2 publication Critical patent/AR131189A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicación 1: Un proceso para producir un compuesto intermediario de diazabiciclo[3.2.1]octano-2-carboxamida, en donde el intermediario tiene la fórmula (III) en donde OBn es benciloxi, y R¹ es 2,5-dioxopirrolidin-1-ilo, 1,3-dioxo-3a,4,7,7a-tetrahidro-1H-isoindol-2(3H)-ilo, 1,3-dioxohexahidro-1H-isoindol-2(3H)-ilo o 3,5-dioxo-4-azatriciclo[5.2.1.0²,⁶]dec-8-en-4-ilo, caracterizado porque comprende: (ii) permitir que un agente de carbonilación seleccionado de fosgeno, difosgeno y trifosgeno actúe sobre un compuesto de fórmula (II), en donde R² es hidrógeno y P es un grupo protector NH capaz de ser removido con ácido, seguido de: (iii) eliminación del grupo protector P, y tratamiento con una base para producir el compuesto de fórmula (III).
ARP230103208A 2013-09-24 2023-11-28 Proceso para producir derivado de diazabiciclooctano y su intermediario AR131189A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013197110 2013-09-24

Publications (1)

Publication Number Publication Date
AR131189A2 true AR131189A2 (es) 2025-02-26

Family

ID=52743343

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP140103525A AR097744A1 (es) 2013-09-24 2014-09-24 Proceso para producir derivado de diazabiciclooctano y su intermediario
ARP230103209A AR131190A2 (es) 2013-09-24 2023-11-28 Derivado de diazabiciclooctano intermediario
ARP230103205A AR131186A2 (es) 2013-09-24 2023-11-28 Proceso para producir derivado de diazabiciclooctano y su intermediario
ARP230103208A AR131189A2 (es) 2013-09-24 2023-11-28 Proceso para producir derivado de diazabiciclooctano y su intermediario
ARP230103207A AR131188A2 (es) 2013-09-24 2023-11-28 Proceso para producir derivado de diazabiciclooctano y su intermediario

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ARP140103525A AR097744A1 (es) 2013-09-24 2014-09-24 Proceso para producir derivado de diazabiciclooctano y su intermediario
ARP230103209A AR131190A2 (es) 2013-09-24 2023-11-28 Derivado de diazabiciclooctano intermediario
ARP230103205A AR131186A2 (es) 2013-09-24 2023-11-28 Proceso para producir derivado de diazabiciclooctano y su intermediario

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230103207A AR131188A2 (es) 2013-09-24 2023-11-28 Proceso para producir derivado de diazabiciclooctano y su intermediario

Country Status (22)

Country Link
US (2) US10000491B2 (es)
EP (1) EP3050883B1 (es)
JP (1) JP6453222B2 (es)
KR (1) KR102239725B1 (es)
CN (2) CN107501264A (es)
AR (5) AR097744A1 (es)
AU (1) AU2014324302B2 (es)
BR (1) BR112016006246B8 (es)
CA (1) CA2924953C (es)
DK (1) DK3050883T3 (es)
ES (1) ES2793201T3 (es)
HK (1) HK1244487A1 (es)
HU (1) HUE049027T2 (es)
IL (1) IL244740B (es)
MX (2) MX372585B (es)
MY (2) MY193210A (es)
NZ (1) NZ718009A (es)
RU (1) RU2719480C2 (es)
SG (1) SG11201602256UA (es)
TW (1) TWI644908B (es)
WO (1) WO2015046207A1 (es)
ZA (1) ZA201602053B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857401B8 (en) * 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
US10000491B2 (en) 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative and intermediate thereof
NZ719568A (en) * 2013-10-08 2018-06-29 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
AU2015355970B2 (en) 2014-12-05 2020-05-21 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
CA2944306C (en) 2015-10-30 2023-11-14 The Toronto-Dominion Bank Validating encrypted data from a multi-layer token
US11216808B2 (en) 2015-11-04 2022-01-04 The Toronto-Dominion Bank Token-based system for excising data from databases
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
CN111447924A (zh) 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
WO2019064071A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO2019064066A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN111373033A (zh) 2017-11-23 2020-07-03 豪夫迈·罗氏有限公司 脯氨酸羟化酶及其相关用途、方法和产品
US11957690B2 (en) 2018-07-16 2024-04-16 Brown University Chromogenic beta-lactamase substrate
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
US11751775B2 (en) 2019-08-30 2023-09-12 DePuy Synthes Products, Inc. Electrical device for monitoring, prevention, and treatment of implant infections
US12509559B2 (en) 2019-10-28 2025-12-30 Brown University Bacterial beta-lactamase responsive hydrogels
CN121021508A (zh) * 2025-10-29 2025-11-28 北京耀诚惠仁科技有限公司 β-内酰胺酶抑制剂中间体共晶或盐及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (es) 1970-10-21 1975-12-10
JPS538509A (en) 1976-07-13 1978-01-26 Toshiba Corp Impedance matching system for data transmission circuit
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
CN1048248C (zh) 1994-05-02 2000-01-12 盐野义制药株式会社 吡咯烷基硫基碳代青霉烯衍生物的结晶、含该结晶的冷冻干燥制剂及其制造方法
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2815420B1 (fr) 2000-10-16 2003-05-16 Cit Alcatel Compensation de la dispersion chromatique dans un systeme de transmission a fibre optique, et fibre de compensation
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
SI2657234T1 (sl) * 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
JP6023800B2 (ja) 2011-06-17 2016-11-09 アストラゼネカ アクチボラグ trans−7−オキソ−6−(スルホオキシ)−1,6−ジアザビシクロ[3,2,1]オクタン−2−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法
EP2748165B1 (en) 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
PT2872510T (pt) 2011-08-30 2017-03-01 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
AU2012310136B2 (en) 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2857401B8 (en) 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
US10000491B2 (en) 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative and intermediate thereof
NZ719568A (en) 2013-10-08 2018-06-29 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Also Published As

Publication number Publication date
DK3050883T3 (da) 2020-05-25
MY176278A (en) 2020-07-27
MX2016003867A (es) 2016-08-04
RU2016115767A (ru) 2017-10-26
US10000491B2 (en) 2018-06-19
RU2719480C2 (ru) 2020-04-17
CN105555787A (zh) 2016-05-04
US20160264573A1 (en) 2016-09-15
BR112016006246A2 (es) 2017-08-22
AR131190A2 (es) 2025-02-26
CN107501264A (zh) 2017-12-22
CA2924953A1 (en) 2015-04-02
MY193210A (en) 2022-09-26
MX372585B (es) 2020-04-17
CA2924953C (en) 2021-12-07
WO2015046207A1 (ja) 2015-04-02
SG11201602256UA (en) 2016-04-28
TWI644908B (zh) 2018-12-21
JP6453222B2 (ja) 2019-01-16
BR112016006246B8 (pt) 2021-10-05
AR131186A2 (es) 2025-02-26
AR097744A1 (es) 2016-04-13
IL244740B (en) 2018-11-29
ZA201602053B (en) 2019-06-26
BR112016006246B1 (pt) 2021-09-08
AU2014324302B2 (en) 2018-02-15
ES2793201T3 (es) 2020-11-13
RU2016115767A3 (es) 2018-06-29
AR131188A2 (es) 2025-02-26
EP3050883A1 (en) 2016-08-03
HK1219473A1 (zh) 2017-04-07
HK1244487A1 (zh) 2018-08-10
KR102239725B1 (ko) 2021-04-12
US20170283415A1 (en) 2017-10-05
US10000492B2 (en) 2018-06-19
HUE049027T2 (hu) 2020-08-28
AU2014324302A1 (en) 2016-05-12
MX367578B (es) 2019-08-27
EP3050883A4 (en) 2017-05-10
EP3050883B1 (en) 2020-04-22
TW201546059A (zh) 2015-12-16
IL244740A0 (en) 2016-04-21
KR20160058851A (ko) 2016-05-25
NZ718009A (en) 2018-03-23
CN105555787B (zh) 2017-08-08
JPWO2015046207A1 (ja) 2017-03-09

Similar Documents

Publication Publication Date Title
AR131189A2 (es) Proceso para producir derivado de diazabiciclooctano y su intermediario
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
AR132029A2 (es) Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
MX381417B (es) Inhibidores de glucosidasa.
ECSP18053634A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20150611A (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
AR088092A1 (es) Procesos para preparar inhibidores de quinasas atr utiles para el tratamiento del cancer
BR112017021803A2 (pt) derivados bicíclicos de quinazolinona
MX2017000408A (es) Compuestos antiproliferativos y métodos de uso de los mismos.
MX386616B (es) Compuestos de carfilzomib pegilados.
UY35567A (es) ?derivados de 3-((2s,5s)-4-metilen-5-(3- oxopropil)tetrahidrofuran-2-il)propanol, su preparación e intermediarios útiles para la misma?.
CY1119296T1 (el) Ενωση δικαρβοξυλικου οξεος
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
CU20170007A7 (es) Compuestos de imidazopiridazina
AR110527A1 (es) Proceso para la preparación de compuestos de benzoxazepina oxazolidinona
MX2018011721A (es) Compuesto de griseofulvina.
MX374426B (es) Sintesis de compuestos de triacetonadiamina mediante procedimiento de aminacion reductora de triacetonadiamina y derivados de los mismos.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2017008957A (es) Síntesis de compuestos de triacetonadiamina mediante aminación reductiva a partir de triacetonadiamina y derivados de estos.
BR112016001928A2 (pt) derivados de piperidina ureia